1. What side effect is more prevalent with abemaciclib than with palbociclib or ribociclib?

2. Which statement best describes the mechanism of action of CDK 4/6 inhibitors?

3. Which CDK 4/6 inhibitor(s) has/have favorable data in phase 3 clinical trials for use in the first-line setting in newly diagnosed premenopausal metastatic breast cancer in combination with aromatase inhibitors?

« Return to Activity